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aItalyBackground: Recent studies have described neo-atherosclerosis, developing inside the stent, as cause of very late
stent thrombosis.
Case report: A 59-year-old man, with family history of coronary artery disease, presented to our Department
because of anterior ST-segment elevation myocardial infarction. Two years before he had underwent percutaneous
coronary intervention with multiple drug-eluting stents (DES) implantation on proximal-mid left anterior descend-
ing artery (LAD), and mid-right coronary artery (RCA), respectively. The angiogram revealed stent thrombosis with
total occlusion of proximal LAD. Multiple passages with manual thrombus-aspiration catheter were successfully
performed with improvement in TIMI flow. Optical Coherence Tomography (OCT) imaging revealed fully
expanded stents without areas of inappropriate apposition to vessel wall; and mild to moderate intimal hyperplasia
throughout the stented segment, with full covered stent struts; areas of ulcerated and ruptured plaque within the
proximal struts of stented segment was depicted with intraluminal protruding material. Thus, an additional bare
metal stent (BMS) was deployed inside and overlapping the previous in order to seal this plaque. OCT post proce-
dure revealed optimal stent expansion and apposition, without residual protruding material. At 9-month follow-up
patient was alive and free from symptoms. Coronary angiogram revealed patency of implanted stents without sig-
nificant restenosis.
Conclusions: Neo-atherosclerosis with thrombosis on top of ruptured necrotic plaque core may play a role in the
pathophysiology of very late stent thrombosis in both BMS and DES. Our report highlights the role OCT to assess
the mechanism of VLST.
 2014 Production and hosting by Elsevier B.V. on behalf of King Saud University.
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Percutaneous coronary intervention (PCI) withstent implantation is the most widely per-
formed procedure for the treatment of acute coro-
nary syndromes. Mechanisms of late stentthrombosis (LST) and very late stent thrombosis
(VLST) have been described and are mainly
linked to delayed or incomplete stent strut end-
othelization, local hypersensitivity reactions, and
late stent malapposition [1–3]. Neo-atherosclerosis
inside a previously implanted coronary stent has
Abbreviations
LAD left anterior descending artery







J Saudi Heart Assoc
2014;26:226–230
AL MAMARY ET AL 227
NEO-ATHEROSCLEROSIS IN VERY LATE STENT THROMBOSIS OF DRUG ELUTING STENTrecently been identified as an additional entity
potentially linked to the development of very
late in-stent restenosis and very late thrombosis
[4].OCT Optical Coherence Tomography
RAO right anterior oblique
VLST very late stent thrombosisCase report
A 59-year-old man with a family history of coro-
nary artery disease presented to our department
because of anterior ST-segment elevation myocar-
dial infarction. Two years previously he under-
went percutaneous coronary intervention of left
anterior descending artery (LAD) and right coro-
nary artery (RCA) with multiple sirolimus-eluting
stents (SES) implantation on proximal-to-mid
LAD (Cypher 3.0/12, 3.0/18, 2.5/18 mm; Cordis
Corp, Warren, NJ, USA), and on proximal RCA
(Cypher 3.5/38 mm), respectively. At presentation,
250 mg IV aspirin and prasugrel 60 mg orally,
were administered. Coronary angiography was
promptly accomplished by right radial artery.
The angiogram revealed stent thrombosis with to-
tal occlusion of proximal LAD (TIMI 0) (Fig. 1a–c).
After guide-wire advancement in the distal vessel,
multiple passages with manual thrombus-aspira-
tion catheter were successfully performed (Export
AP 6F; Medtronic Inc. Minneapolis, MN, USA).Figure 1. Diagnostic angiogram demonstrates VLST of proximal LAD in d
months’ follow-up angiogram in cranial AP view (d).Significant reduction in thrombus burden with
improvement in TIMI flow was achieved. Optical
Coherence Tomography (OCT) (C7 Dragonfly,
LightLab Imaging Inc. Westford, MA, USA) imag-
ing was applied in order to investigate the stent
struts-to-vessel boundary and to identify the
mechanisms of stent thrombosis. OCT revealed
fully expanded stents without areas of inappropri-
ate apposition to vessel wall; and mild to moder-
ate intimal hyperplasia throughout the stented
segment with fully covered stent struts.
Interestingly, in the proximal segment of the
stents, areas of ulcerated and ruptured plaque
with intraluminal protruding material were seen
(Figs. 2 and 3). Thus, an additional bare metal
stent (BMS) (Multi-link Vision 3.0 x 23 mm; Abbott
Vascular, Santa Clara, CA, USA) was deployed in-
side, and overlapping the previous one, in order to






Figure 2. OCT images of proximal-mid LAD, showing mild neointimal hyperplasia (a and b) in the mid stent segment, and in the proximal
segment thin-cap fibroatheroma extending proximally to strut, with a large lipid core, area of plaque rupture and thrombus protruding into the
lumen (c–f).
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months’ follow-up, the patient was alive and free
from symptoms. Coronary angiogram revealed
patency of implanted stents without significant
restenosis (Fig. 1d).Discussion
Although first generation sirolimus and paclit-
axel drug-eluting stents (DES) have radically re-
duced restenosis rates at short and mid-term,
late stent thrombosis (LST) and very late stent
thrombosis (VLST) as well as late catch-up, have
emerged as important drawbacks of this technol-
ogy [5]. Definitions of stent thrombosis (ST) range
from ‘angiographically proven’ to ‘clinically sus-
pected’ ST with the inclusion of myocardial infarc-
tion (MI) involving the target vessel to
unexplained death (within 30 days or anytime).
The Academic Research Consortium has pro-
posed a new standardized definition of ST based
on two principles. The first is the level of certainty
that ST is the underlying mechanism of adverse
event and time of adverse event relative to indexprocedure. Definite ST (highest level of certainty)
requires either angiographic or post-mortem
evidence of thrombotic stent occlusion. Probable
ST encompasses any unexplained death within
30 days of stent implantation or any MI in the ter-
ritory of the implanted stent regardless of time.
Possible ST includes any unexplained death
beyond 30 days until the end of follow-up. The
second classification principle is based on the time
of the adverse event relative to the index proce-
dure. Early ST refers to the first 30 days after stent
implantation and is further stratified into acute
(24 h) and sub-acute (24 h to 30 days). Late ST de-
fines the time interval between one month and
one year after stent implantation; very late ST in-
cludes any event beyond one year [6,7]. Premature
antiplatelet therapy discontinuation, renal failure,
bifurcation lesions, diabetes, and low ejection
fraction, total stent length, total stent number,
and small stent size were identified as predictors
of early, late, and very late stent thrombosis
events [8,9]. Moreover, it is reported that drug-
eluting stent is the only independent predictor of








Figure 3. Image magnification of Fig. 1d–e, showing stent struts, yellow arrow (a); ulcerated plaque with thrombus protruding into lumen, white
arrows (a and b); and plaque rupture at thin cap, black arrow (b).
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tivity reactions, and late stent malapposition due
to positive remodelling may be possible mecha-
nisms for LST and VLST after DES implantation
[1–3]. More recently, the growth of neointimal ath-
erosclerosis (neo-atherosclerosis) inside a previ-
ously implanted coronary stent has been
identified as a new entity potentially linked with
the development of late catch-up and late throm-
bosis [4]. Neo-atherosclerosis has been reported in
both BMS and DES; however, after DES implanta-
tion, neo-atherosclerosis has been observed at an
earlier time-point than that of BMS. The underly-
ing mechanisms responsible for the development
of neo-atherosclerosis following stent implanta-
tion are likely multifactorial, and related to lack
of functional endothelialized luminal surface
within the stented segment [4]. Neo-atherosclero-
sis is characterized by infiltration of foamy macro-
phage clusters within the neointima, and thin-cap
fibroatheroma (TCFA). Studies demonstrate that
neointimal rupture during an extended period
contribute to late stent failure [11,12]. In-stent
development of TCFA neointima with neointimal
rupture has been associated with thrombotic
events and clinical sequelae after stent implanta-
tion [13]. Optical Coherent Tomography (OCT) is
able to detect late catch-up phenomena, as well
as TCFA, neointimal rupture, neovascularization
and intramural thrombi after DES implantation
[14]. ST constitutes an emergency, be it early, late,
or very late, just like any acute MI. Primary PCI is
the therapy of choice, the goal being to mechani-
cally recanalize the thrombosed stent. Procedural
success in >90% of patients has been reported.
Most thrombotic stent occlusions can be treated
with balloon angioplasty alone, perhaps aided bythrombus aspiration. Additional stent implanta-
tion should be limited to significant residual ste-
nosis/dissections [7].
Our report highlights the relevance of OCT in
assessing the pathological basis and mechanisms
of very late stent thrombosis and the choice of
appropriate management of stent failure. Accord-
ingly, in the present case, OCT imaging clearly de-
tected TCFA within the struts of previously
implanted DES, with areas of ruptured plaque
and superimposed thrombus, as a correlate of
VLST. Our case reflects the findings recently re-
ported by Kang and colleagues that VLST is
mostly associated with neointimal rupture and
area of lipid core, and that it is less associated with
mechanical trouble like uncovered stent struts,
frames malapposition or stent fracture. The
authors concluded that neointimal rupture more
likely contributed to the thrombotic event due to
the spatial relationship of the intracoronary
thrombus to the site of neointimal rupture [13].
Furthermore, our case appears in agreement with
the recent findings of Habara et al. who described
different OCT patterns of in-stent restenosis
according to different time-points. Particularly,
they found that TCFA-like patterns and intralumi-
nal material were more frequently observed in
very late in-stent restenosis than in patients with
early in-stent restenosis, suggesting that neo-ath-
erosclerosis contributes not only to VLST but also
to late catch-up phenomena [15]. Interestingly, we
performed a BMS in-stent implantation in order to
seal a ruptured plaque, and to reduce further
recurrence of late stent failure. However, in this
regard, it is important to consider that definite
treatment of VLST, due to neo-atherosclerosis, is
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drug-eluting stents are attractive in this setting,
the consequences of the eluted drug on the vessel
wall healing process remain unresolved.Conclusions
Neo-atherosclerosis with thrombosis on top of
ruptured necrotic plaque core seems to play a role
in the pathophysiology of very late stent thrombo-
sis in both BMS and DES. Our report highlights
the role of OCT to assess the mechanism of VLST.Conflict of interest
There is no conflict of interest to declare.
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